SG11201505615PA - Site-specific insulin conjugate - Google Patents

Site-specific insulin conjugate

Info

Publication number
SG11201505615PA
SG11201505615PA SG11201505615PA SG11201505615PA SG11201505615PA SG 11201505615P A SG11201505615P A SG 11201505615PA SG 11201505615P A SG11201505615P A SG 11201505615PA SG 11201505615P A SG11201505615P A SG 11201505615PA SG 11201505615P A SG11201505615P A SG 11201505615PA
Authority
SG
Singapore
Prior art keywords
site
insulin conjugate
specific insulin
specific
conjugate
Prior art date
Application number
SG11201505615PA
Inventor
Myung Hyun Jang
Dae Jin Kim
Sang Youn Hwang
Hyun Uk Kim
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SG11201505615PA publication Critical patent/SG11201505615PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201505615PA 2013-02-26 2014-02-26 Site-specific insulin conjugate SG11201505615PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130020703 2013-02-26
PCT/KR2014/001597 WO2014133327A1 (en) 2013-02-26 2014-02-26 Site-specific insulin conjugate

Publications (1)

Publication Number Publication Date
SG11201505615PA true SG11201505615PA (en) 2015-09-29

Family

ID=51428525

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505615PA SG11201505615PA (en) 2013-02-26 2014-02-26 Site-specific insulin conjugate

Country Status (22)

Country Link
US (1) US10046061B2 (en)
EP (1) EP2963055B1 (en)
JP (1) JP6465817B2 (en)
KR (1) KR102185311B1 (en)
CN (1) CN105229025B (en)
AR (1) AR094904A1 (en)
AU (1) AU2014221534B2 (en)
BR (1) BR112015018828B1 (en)
CA (1) CA2899418C (en)
ES (1) ES2738676T3 (en)
HK (1) HK1217202A1 (en)
IL (1) IL240714B (en)
MX (1) MX361083B (en)
NZ (1) NZ710564A (en)
PH (1) PH12015501815A1 (en)
PT (1) PT2963055T (en)
RU (1) RU2677800C2 (en)
SA (1) SA515360887B1 (en)
SG (1) SG11201505615PA (en)
TR (1) TR201910929T4 (en)
WO (1) WO2014133327A1 (en)
ZA (1) ZA201507105B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
AR090281A1 (en) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
EP3260139A4 (en) * 2015-02-17 2018-09-05 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue complex
AR105616A1 (en) 2015-05-07 2017-10-25 Lilly Co Eli FUSION PROTEINS
UY36870A (en) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd NEW INSULIN ANALOGS
EP3517544A4 (en) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. Insulin analog having reduced binding force to insulin receptor, and use thereof
MX2019011297A (en) 2017-03-23 2019-11-12 Hanmi Pharm Ind Co Ltd Insulin analog complex with reduced affinity for insulin receptor and use thereof.
JP2020535199A (en) * 2017-09-29 2020-12-03 ハンミ ファーマシューティカル カンパニー リミテッド Persistent protein conjugate with improved potency

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
KR101135244B1 (en) * 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
WO2007140282A1 (en) 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
BRPI1013626B8 (en) * 2009-03-20 2021-05-25 Hanmi Holdings Co Ltd method for preparing site-specific physiologically active polypeptide conjugate
AR081066A1 (en) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
KR101330868B1 (en) * 2010-06-08 2013-11-18 한미사이언스 주식회사 Insulin derivative drug conjugate using an immunoglobulin fragment
CN103068842B (en) 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 Insulin receptor INSR is had highly active single-chain insulin agonist
JP2014509603A (en) * 2011-03-15 2014-04-21 ノヴォ ノルディスク アー/エス Human insulin analogues and human insulin derivatives containing cysteine substitutions
CN102675452B (en) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 Tool continues the conjugate of insulin human that is hypoglycemic and that combined by height and analogue
CN103747806A (en) * 2011-06-02 2014-04-23 韩美科学株式会社 Non-peptidyl polymer-insulin multimer and method for producing same
UA113626C2 (en) * 2011-06-02 2017-02-27 A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE

Also Published As

Publication number Publication date
PH12015501815B1 (en) 2015-12-07
PH12015501815A1 (en) 2015-12-07
IL240714A0 (en) 2015-10-29
KR102185311B1 (en) 2020-12-01
KR20140106455A (en) 2014-09-03
BR112015018828B1 (en) 2024-01-30
RU2015133462A (en) 2017-03-31
EP2963055A4 (en) 2016-10-19
US10046061B2 (en) 2018-08-14
AR094904A1 (en) 2015-09-09
ES2738676T3 (en) 2020-01-24
IL240714B (en) 2020-05-31
CN105229025B (en) 2019-11-19
SA515360887B1 (en) 2018-10-25
EP2963055A1 (en) 2016-01-06
US20160000931A1 (en) 2016-01-07
BR112015018828A2 (en) 2017-08-15
NZ710564A (en) 2020-06-26
PT2963055T (en) 2019-07-25
RU2677800C2 (en) 2019-01-21
MX2015009799A (en) 2015-10-29
TR201910929T4 (en) 2019-08-21
ZA201507105B (en) 2017-11-29
CN105229025A (en) 2016-01-06
CA2899418A1 (en) 2014-09-04
CA2899418C (en) 2022-05-03
AU2014221534A1 (en) 2015-08-20
HK1217202A1 (en) 2016-12-30
JP2016510004A (en) 2016-04-04
EP2963055B1 (en) 2019-05-15
AU2014221534B2 (en) 2018-06-28
JP6465817B2 (en) 2019-02-06
WO2014133327A1 (en) 2014-09-04
MX361083B (en) 2018-11-27

Similar Documents

Publication Publication Date Title
HRP20190056T1 (en) Anti-trop2 antibody-drug conjugate
ZA201905426B (en) Drug combinations
HRP20180684T1 (en) Drug combination
IL244816B (en) Protein-polymer-drug conjugates
IL245009A0 (en) Protein-polymer-drug conjugates
EP2970511A4 (en) Insulin-incretin conjugates
SG11201605260VA (en) Var2csa-drug conjugates
ZA201506252B (en) Syringe
HK1217202A1 (en) Site-specific insulin conjugate
EP2968381A4 (en) Sugar-linker-drug conjugates
EP2978473A4 (en) Auto-retractible syringe
GB201404608D0 (en) Nickel direct-plating
GB201321335D0 (en) Top-Up
AU353529S (en) Toaster
AU353447S (en) Toaster
GB201313186D0 (en) Toaster